The Relative Strength (RS) Rating for Gilead Sciences entered a new percentile Friday, with a rise from 78 to 84.
As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength.
IBD's unique rating measures market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history shows that the top-performing stocks tend to have an RS Rating north of 80 in the early stages of their moves.
See How IBD Helps You Make More Money In Stocks
Gilead Sciences is working on a long consolidation with a 74.22 buy point. See if the stock can continue to move up and clear the breakout price in heavy trade.
Gilead Sciences reported -13% earnings growth in its most recent report. Revenue increased 1%.
The company earns the No. 54 rank among its peers in the Medical-Biomed/Biotech industry group. Genmab and Vertex Pharmaceuticals are also among the group's highest-rated stocks.
Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks
